Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage

Haass, NK; Nassif, N; McGowan, EM

Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage

Haass, NK Nassif, N

McGowan, EM

Permalink

Publication Type:: Journal Article
Citation:: BioMed Research International, 2015, 2015
Issue Date:: 2015-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (1.39 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Haass, NK	en_US
dc.contributor.author	Nassif, N https://orcid.org/0000-0003-2675-8322	en_US
dc.contributor.author	McGowan, EM https://orcid.org/0000-0001-6371-3751	en_US
dc.date.available	2014-10-16	en_US
dc.date.issued	2015-01-01	en_US
dc.identifier.citation	BioMed Research International, 2015, 2015	en_US
dc.identifier.issn	2314-6133	en_US
dc.identifier.uri	http://hdl.handle.net/10453/37585
dc.description.abstract	© 2015 Nikolas K. Haass et al. Cancer and diabetes are among the most common diseases in western societies. Epidemiological studies have shown that diabetic patients have a significantly higher risk of developing a number of different types of cancers and that individuals with comorbidity (cancer and diabetes/prediabetes) have a poorer prognosis relative to nondiabetic cancer patients. The increasing frequency of comorbidity of cancer and diabetes mellitus, mainly type 2 diabetes, has driven the development of therapeutic interventions that target both disease states. There is strong evidence to suggest that balancing the sphingolipid rheostat, ceramide - sphingosine - sphingosine-1-phosphate (S1P) is crucial in the prevention of diabetes and cancer and sphingosine kinase/S1P modulators are currently under development for the treatment of cancer and diabetes. This paper will highlight some of the complexities inherent in the use of the emerging sphingosine kinase/S1P modulators in the treatment of comorbidity of diabetes and cancer.	en_US
dc.relation.ispartof	BioMed Research International	en_US
dc.relation.isbasedon	10.1155/2015/165105	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Neoplasms	en_US
dc.subject.mesh	Diabetes Mellitus, Type 2	en_US
dc.subject.mesh	Sphingolipids	en_US
dc.subject.mesh	Comorbidity	en_US
dc.title	Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage	en_US
dc.type	Journal Article
utslib.citation.volume	2015	en_US
utslib.for	060405 Gene Expression (incl. Microarray and other genome-wide approaches)	en_US
utslib.for	0605 Microbiology	en_US
utslib.for	06 Biological Sciences	en_US
utslib.for	08 Information and Computing Sciences	en_US
utslib.for	10 Technology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access
pubs.publication-status	Published	en_US
pubs.volume	2015	en_US

Abstract:

© 2015 Nikolas K. Haass et al. Cancer and diabetes are among the most common diseases in western societies. Epidemiological studies have shown that diabetic patients have a significantly higher risk of developing a number of different types of cancers and that individuals with comorbidity (cancer and diabetes/prediabetes) have a poorer prognosis relative to nondiabetic cancer patients. The increasing frequency of comorbidity of cancer and diabetes mellitus, mainly type 2 diabetes, has driven the development of therapeutic interventions that target both disease states. There is strong evidence to suggest that balancing the sphingolipid rheostat, ceramide - sphingosine - sphingosine-1-phosphate (S1P) is crucial in the prevention of diabetes and cancer and sphingosine kinase/S1P modulators are currently under development for the treatment of cancer and diabetes. This paper will highlight some of the complexities inherent in the use of the emerging sphingosine kinase/S1P modulators in the treatment of comorbidity of diabetes and cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/37585